Search

Displaying results 4301 - 4310 of 7897 in total
  1. Drug

    (R)-warfarin

    go.drugbank.com/drugs/DB08496
    Experimental

    S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A1038] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

  2. Drug

    5-deoxyflavanone

    go.drugbank.com/drugs/DB03601
    Experimental

    These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3. … 5-deoxyflavanone is a solid. This compound belongs to the flavanones.

  3. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is a small molecule drug. … Canosimibe has a monoisotopic molecular weight of 809.43 Da.

  4. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant is a small molecule drug. … Rintodestrant has a monoisotopic molecular weight of 462.09 Da.

  5. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  6. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  7. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. … It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models.

  8. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as serious adverse events and injection reactions such as fever and chills have been reported. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.

  9. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions.

  10. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.